Biotechnology
Bio-Thera Wins China Approval for Golimumab Biosimilar ASHULI
Bio-Thera Solutions announced on November 6, 2026 that China’s National Medical Products Administration (NMPA) had approved its marketing authorization for BAT2506, a golimumab biosimilar that will be marketed as ASHULI for rheumatoid arthritis and ankylosing spondylitis. The decision adds China…
Lilly and Hims & Hers Formalize Self-Pay Obesity Drug Access
Eli Lilly and Hims & Hers announced an agreement on November 6, 2026 to expand access to Zepbound and Foundayo through the Hims & Hers platform. Eligible patients prescribed either medicine by a licensed provider on the platform will have…
Halozyme Raises 2026 Guidance as Royalty Revenue Jumps 44%
Halozyme Therapeutics reported its third-quarter results on November 5, 2026, posting a 39% year-over-year revenue increase to $493.0 million and raising its full-year 2026 guidance for revenue, royalties, adjusted EBITDA and non-GAAP diluted earnings per share. The results covered the…
Ginkgo Bioworks Narrows Q3 Loss and Signs Novo Lab Deal
Ginkgo Bioworks announced on November 5, 2026 that its third-quarter GAAP net loss from continuing operations narrowed to $41 million from $73 million a year earlier, alongside its first autonomous-lab sale to a top-tier pharmaceutical company, Novo. The year-over-year improvement…
Guardant Health Lifts 2026 Revenue Outlook as Screening Surges
Guardant Health announced on November 5, 2026 that it raised its full-year revenue outlook to $1.36 billion to $1.37 billion after third-quarter revenue increased 36% to $361.0 million, led by growth in Oncology and its Shield cancer-screening business. The new…
Amphastar Q3 Net Income Rises to $37.8 Million as Revenue Grows 8%
Amphastar Pharmaceuticals reported on November 5, 2026 that net revenue for the third quarter ended September 30, 2026 rose 8% year over year to $207.6 million, while GAAP net income increased to $37.8 million from $17.4 million. Diluted earnings were…
Enliven Q3 Loss Widens to $27.7 Million Ahead of First Pivotal Trial
Enliven Therapeutics reported third-quarter 2026 results on November 5, 2026, posting a net loss of $27.7 million for the quarter ended September 30, compared with $20.1 million a year earlier, as the clinical-stage company prepared for its first pivotal trial.…
Regenxbio Q3 Loss Narrows With Settlement Gain as Revenue Falls
REGENXBIO reported on November 5, 2026, that its third-quarter net loss narrowed to $40.7 million from $61.9 million a year earlier. A gain from the Sarepta Therapeutics patent-litigation settlement helped improve the bottom line even as royalty revenue contracted and…
Intensity Therapeutics Q3 Loss Widens as Trial Enrollment Resumes
Intensity Therapeutics reported a third-quarter 2026 net loss of $3.54 million on November 5, 2026, compared with $2.67 million in the same quarter of 2025, as new-patient enrollment activities resumed in its Phase 3 soft-tissue sarcoma study. The higher research…
Intellia Q3 Loss Widens to $127.5 Million as Launch Costs Rise
Intellia Therapeutics reported third-quarter results on November 5, 2026, showing a net loss of $127.5 million, up from $101.3 million in the third quarter of 2025. Higher commercial-launch spending and lower collaboration revenue offset a reduction in research costs, while…
Akeso’s Ivonescimab Wins China Priority Review in Biliary Cancer
Akeso announced on November 4, 2026 that China’s National Medical Products Administration had granted Priority Review to ivonescimab plus chemotherapy for first-line treatment of locally advanced or metastatic biliary tract cancer. The designation is expected to accelerate the subsequent regulatory…
Adaptive Biotechnologies Raises MRD Outlook After Q3 Profit
Adaptive Biotechnologies reported third-quarter results on November 4, 2026, posting net income of $2.8 million and raising its full-year outlook for minimal residual disease (MRD) revenue as clonoSEQ test volume and core MRD revenue grew sharply. The company now expects…
Schrödinger Raises 2026 Outlook as Q3 Revenue Grows 19%
Schrödinger raised its full-year 2026 annual contract value (ACV) and drug-discovery revenue guidance on November 4, 2026, when it reported third-quarter revenue of $64.5 million, up 19% from a year earlier. Under the revised forecast, full-year ACV is $222 million…
Ryvu Reports Early Dapolsertib Data in Phase II Lymphoma Trial
Ryvu Therapeutics and Menarini Group announced on November 4, 2026 the first clinical data from the Phase II JASPIS-01 study of dapolsertib monotherapy in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: four of the 15 patients treated by the data…
Amgen Raises 2026 Outlook as Q3 Revenue Grows 8% to $10.4 Billion
Amgen announced third-quarter 2026 results on November 3, 2026, reporting an 8% year-over-year increase in total revenue to $10.365 billion and raising its full-year revenue and adjusted earnings per share (EPS) outlook. Product sales also rose 8% to $9.883 billion,…
